Fig. 1: Participant flow in the study of repeated-dose intravenous ketamine for depression.

A total of 257 patients were assessed for eligibility. One hundred and thirty-five patients met inclusion criteria and received ketamine treatment, with 117 patients completing the six infusions. Ultimately, data from these 117 patients were included in the analysis.